Physician profile
Gerthy Michel
NPI 1679120612
$7,599.45
in general payments reported to CMS, 2019-2025
27 companies · $3,168 in 2025
The $3,168 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,102 · 2022: $919 · 2023: $431 · 2024: $1,979 · 2025: $3,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,497 · Education: $80.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,497.33 |
| Education | $80.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,667.96 | 2021-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,072.08 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $811.58 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Lilly USA, LLC | $383.04 | 2023-2025 | Omvoh |
| Astrazeneca Pharmaceuticals LP | $370.17 | 2021-2025 | Wainua |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.47 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $198.85 | 2022 | |
| Idorsia Pharmaceuticals US INC | $146.58 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2024 | |
| G1 Therapeutics, INC. | $124.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.60 | 2022 | |
| Glaxosmithkline, LLC. | $119.85 | 2024 | |
| Sun Pharmaceutical Industries INC. | $118.64 | 2021 | |
| Aimmune Therapeutics, INC. | $111.45 | 2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $111.31 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $109.07 | 2021 | |
| Celgene Corporation | $108.66 | 2021 | |
| Qol Medical, LLC | $105.62 | 2024-2025 | Sucraid, Sucraid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $104.02 | 2021 | |
| Seagen INC. | $99.51 | 2021 | |
| Biogen, INC. | $96.75 | 2023 | |
| Daiichi Sankyo INC. | $70.43 | 2021-2022 | |
| Pfizer INC. | $63.59 | 2024 | |
| Celltrion USA INC. | $48.20 | 2024 | Zymfentra, Vegzelma |
| Ferring Pharmaceuticals INC. | $27.81 | 2024 | Rebyota |
| Redhill Biopharma INC. | $21.55 | 2021 | |
| Merck Sharp & Dohme LLC | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerthy Michel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.